retatrutide phase 2 nejm weight loss 48 weeks triple agonist π may be redefining obesity treatment. New data from TRIUMPH-1 Trial showed: π₯ ~28% average over 80 π₯ >30% weight loss in nearly half of participant #ObesityMedicine #Retatrutide #GLP1 #CardioMetabolic Results from a new trial
Pay in 4 interest-free payments of $6.57 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours Β· Estimated delivery Aug 19 - Aug 24



















![Cardiovascular disease continuum-GLP-1 action. Adapted from [46]](https://www.researchgate.net/publication/357072789/figure/fig1/AS:1146405179654167@1650335702879/Cardiovascular-disease-continuum-GLP-1-action-Adapted-from-46.png)






